Different anti-HCV profiles of statins and their potential for combination therapy with interferon

Hepatology

Volumn 44, Issue 1, 2006, Pages 117-125

  Ikeda, Masanori ^a   Abe, Ken Ichi ^a   Yamada, Masashi ^a   Dansako, Hiromichi ^a   Naka, Kazuhito ^a   Kato, Nobuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; FLUINDOSTATIN; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; INTERNAL RIBOSOME ENTRY SITE; PRIORITY JOURNAL; RL GENE; RNA REPLICATION; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTERFERON-ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33745903898     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21232     Document Type: Article

References (26)

1. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972.
2. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
3. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002;76:2997-3006.
4. Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002;76:4008-4021.
5. Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002;304:197-210.
6. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
7. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
8. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9299.
9. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 2005;329:1350-1359.
10. Naka K, Ikeda M, Abe K, Dansako H, Kato N. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. Biochem Biophys Res Commun 2005;330:871-879.
11. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003;100:15865-15870.
12. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005;102:2561-2566.
13. Wang C, Gale M Jr, Keller BC, Huang H, Brown MS, Goldstein JL, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18:425-434.
14. Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, et al. Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2000;74:8744-8750.
15. Noguchi M, Hirohashi S. Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. In Vitro Cell Dev Biol Anim 1996;32:135-137.
16. Dansako H, Naganuma A, Nakamura T, Ikeda F, Nozaki A, Kato N. Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res 2003;97:17-30.
17. Kato N, Sugiyama K, Namba K, Dansako H, Nakamura T, Takami M, et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem Biophys Res Commun 2003;306:756-766.
18. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002;30:1400-1405.
19. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-17163.
20. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001;297:861-867.
21. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001;75:1252-1264.
22. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005;43:808-816.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
24. Hwang DR, Tsai YC, Lee JC, Huang KK, Lin RK, Ho CH, et al. Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob Agents Chemother 2004;48:2876-2882.
25. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon L, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-714.
26. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S, et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001;6:351-361.